Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Arava
Arava 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-089662 · Präparat HOS-083907
Effect on repaglinide (CYP2C8 substrate)
There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively),
following repeated doses of A771726, suggesting that A771726 is an inhibitor of CYP2C8 in vivo.
Therefore, monitoring patients with concomitant use of medicinal products metabolised by
CYP2C8, such as repaglinide, paclitaxel, pioglitazone or rosiglitazone, is recommended as they may
have higher exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): repaglinide (HOS-086935) paclitaxel (HOS-087959) pioglitazone (HOS-089663) rosiglitazone (HOS-089664)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage 219c5e23f8df43bf6f18151a39e5f10c7ec1d53bb88fb3c91cd151ce1ff15241 · Zeichen 4158–4594 im Abschnitt
Wechselwirkungen · Arava
Arava 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 26
HOS-089733 · Präparat HOS-083907
Effect on repaglinide (CYP2C8 substrate)
There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively),
following repeated doses of A771726, suggesting that A771726 is an inhibitor of CYP2C8 in vivo.
Therefore, monitoring patients with concomitant use of medicinal products metabolised by
CYP2C8, such as repaglinide, paclitaxel, pioglitazone or rosiglitazone, is recommended as they may
have higher exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pioglitazone (HOS-089663) rosiglitazone (HOS-089664) repaglinide (HOS-086935) paclitaxel (HOS-087959)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage 219c5e23f8df43bf6f18151a39e5f10c7ec1d53bb88fb3c91cd151ce1ff15241 · Zeichen 4160–4596 im Abschnitt
Wechselwirkungen · Arava
Arava 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-089793 · Präparat HOS-083907
Effect on repaglinide (CYP2C8 substrate)
There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively),
following repeated doses of A771726, suggesting that A771726 is an inhibitor of CYP2C8 in vivo.
Therefore, monitoring patients with concomitant use of medicinal products metabolised by
CYP2C8, such as repaglinide, paclitaxel, pioglitazone or rosiglitazone, is recommended as they may
have higher exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): repaglinide (HOS-086935) paclitaxel (HOS-087959) pioglitazone (HOS-089663) rosiglitazone (HOS-089664)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage 219c5e23f8df43bf6f18151a39e5f10c7ec1d53bb88fb3c91cd151ce1ff15241 · Zeichen 4156–4592 im Abschnitt
Wechselwirkungen · Leflunomide Zentiva (previously Leflunomide Winthrop)
Leflunomide Zentiva 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-122357 · Präparat HOS-095511
8
There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively), following
repeated doses of A771726, suggesting that A771726 is an inhibitor of CYP2C8 in vivo. Therefore,
monitoring patients with concomitant use of medicinal products metabolised by CYP2C8, such as
repaglinide, paclitaxel, pioglitazone or rosiglitazone, is recommended as they may have higher
exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): repaglinide (HOS-086935) paclitaxel (HOS-087959) pioglitazone (HOS-089663) rosiglitazone (HOS-089664)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T17:27:00Z · SHA-256 bed6a472e84572491a61af1acb52b0f05e60157fe2f2f53c93e4e488c7c80e1b · Passage c631f87bd0e153dc8aafe431d322fefa1e7a53947273c787e2f9e9e1cd4479eb · Zeichen 4212–4610 im Abschnitt
Wechselwirkungen · Leflunomide Zentiva (previously Leflunomide Winthrop)
Leflunomide Zentiva 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 25–26
HOS-122432 · Präparat HOS-095511
25
Effect on repaglinide (CYP2C8 substrate)
There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively), following
repeated doses of A771726, suggesting that A771726 is an inhibitor of CYP2C8 in vivo. Therefore,
monitoring patients with concomitant use of medicinal products metabolised by CYP2C8, such as
repaglinide, paclitaxel, pioglitazone or rosiglitazone, is recommended as they may have higher
exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): repaglinide (HOS-086935) paclitaxel (HOS-087959) pioglitazone (HOS-089663) rosiglitazone (HOS-089664)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T17:27:00Z · SHA-256 bed6a472e84572491a61af1acb52b0f05e60157fe2f2f53c93e4e488c7c80e1b · Passage c048668b6040ff4c5230a410870bd44c674ae44bdbb0e62e4d52862d50d82913 · Zeichen 4170–4610 im Abschnitt
Wechselwirkungen · Leflunomide Zentiva (previously Leflunomide Winthrop)
Leflunomide Zentiva 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 42–43
HOS-122492 · Präparat HOS-095511
Effect on repaglinide (CYP2C8 substrate)
There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively), following
repeated doses of A771726, suggesting that A771726 is an inhibitor of CYP2C8 in vivo. Therefore,
42
monitoring patients with concomitant use of medicinal products metabolised by CYP2C8, such as
repaglinide, paclitaxel, pioglitazone or rosiglitazone, is recommended as they may have higher
exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): repaglinide (HOS-086935) paclitaxel (HOS-087959) pioglitazone (HOS-089663) rosiglitazone (HOS-089664)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T17:27:00Z · SHA-256 bed6a472e84572491a61af1acb52b0f05e60157fe2f2f53c93e4e488c7c80e1b · Passage 792aa19ba6dfbf55cf1af8600f69754747bae3900d3e3673c1246c392b65f874 · Zeichen 4118–4608 im Abschnitt
Wechselwirkungen · Zytiga
ZYTIGA 250 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-125288 · Präparat HOS-096037
In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone was increased by
46% and the AUCs for M-III and M-IV, the active metabolites of pioglitazone, each decreased by 10%
when pioglitazone was given together with a single dose of 1 000 mg abiraterone acetate. Patients
should be monitored for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic
index if used concomitantly. Examples of medicinal products metabolised by CYP2C8 include
pioglitazone and repaglinide (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pioglitazone (HOS-089663) repaglinide (HOS-086935)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T14:31:00Z · SHA-256 1cd8edc18fae83339cc466c58b27be12ff13a584e8ad30419a21aea3ec2adf1f · Passage 97fd2ecd9a55848a12935feee6e4d47dae88bde2dbabe5f2514aa80c71b3777b · Zeichen 2158–2692 im Abschnitt
Wechselwirkungen · Zytiga
ZYTIGA 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-125315 · Präparat HOS-096037
In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone was increased by
46% and the AUCs for M-III and M-IV, the active metabolites of pioglitazone, each decreased by 10%
when pioglitazone was given together with a single dose of 1 000 mg abiraterone acetate. Patients
should be monitored for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic
index if used concomitantly. Examples of medicinal products metabolised by CYP2C8 include
pioglitazone and repaglinide (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pioglitazone (HOS-089663) repaglinide (HOS-086935)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T14:31:00Z · SHA-256 1cd8edc18fae83339cc466c58b27be12ff13a584e8ad30419a21aea3ec2adf1f · Passage 97fd2ecd9a55848a12935feee6e4d47dae88bde2dbabe5f2514aa80c71b3777b · Zeichen 2158–2692 im Abschnitt
Wechselwirkungen · Aubagio
AUBAGIO 7 mg film-coated tablets AUBAGIO 14 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-126667 · Präparat HOS-096301
Effect of teriflunomide on CYP2C8 substrate: repaglinide
There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively), following
repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of CYP2C8 in vivo.
Therefore, medicinal products metabolised by CYP2C8, such as repaglinide, paclitaxel, pioglitazone
or rosiglitazone, should be used with caution during treatment with teriflunomide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): repaglinide (HOS-086935) paclitaxel (HOS-087959) pioglitazone (HOS-089663) rosiglitazone (HOS-089664)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T14:35:00Z · SHA-256 590c2a61b8e2e029ec7654e3780b1cba8a07adbbaa44e9523484198edf4cb160 · Passage 1b32f798f446d1dbd045a507a4c0ab297632212ecff0a7fc3c41a2cf2dd01a0f · Zeichen 1298–1734 im Abschnitt
Wechselwirkungen · Cresemba
CRESEMBA 200 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9–10
HOS-128908 · Präparat HOS-096645
(Mechanism unknown)
Other anticancer agents Not studied. No isavuconazole dose
(daunorubicin, doxorubicin, Daunorubicin, doxorubicin, adjustment necessary.
imatinib, irinotecan, lapatinib, imatinib, irinotecan, lapatinib, Daunorubicin, doxorubicin,
mitoxantrone, topotecan) mitoxantrone, topotecan imatinib, irinotecan, lapatinib,
(BCRP substrates) concentrations may increase. mitoxantrone or topotecan:
careful monitoring for any
(BCRP inhibition) occurrence of drug toxicity, and
dose reduction if required.
Antiemetics
Aprepitant Not studied. Co-administration should be
(mild CYP3A4/5 inducer) Isavuconazole concentrations may avoided unless the potential
decrease. benefit is considered to outweigh
the risk.
(CYP3A4/5 induction)
Antidiabetics
Metformin Metformin: No isavuconazole dose
(OCT1, OCT2 and MATE1 AUCinf: ↑ 52% adjustment necessary.
substrate) Cmax: ↑ 23% Metformin: dose reduction may
be required.
(OCT2 inhibition)
Repaglinide Repaglinide: No isavuconazole dose
(CYP2C8 and OATP1B1 AUCinf: ↓ 8% adjustment necessary.
substrate) Cmax: ↓ 14% Repaglinide: no dose adjustment
required.
Pioglitazone Not studied. Co-administration should be
(mild CYP3A4/5 inducer) avoided unless the potential
9
Isavuconazole concentrations may benefit is considered to outweigh
decrease. the risk.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daunorubicin (HOS-089674) doxorubicin (HOS-084538) imatinib (HOS-110212) irinotecan (HOS-112102) lapatinib (HOS-122565) mitoxantrone (HOS-124775) topotecan (HOS-086047) aprepitant (HOS-112506) metformin (HOS-091032) repaglinide (HOS-086935) pioglitazone (HOS-089663)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage 854a91e973c77b9e297df129810c589fef8306f228064f2fd1d019fbd0b296bc · Zeichen 11990–14467 im Abschnitt
Wechselwirkungen · Cresemba
CRESEMBA 40 mg hard capsules CRESEMBA 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 32
HOS-128988 · Präparat HOS-096645
(Mechanism unknown)
Other anticancer agents Not studied. No isavuconazole dose
(daunorubicin, doxorubicin, Daunorubicin, doxorubicin, adjustment necessary.
imatinib, irinotecan, lapatinib, imatinib, irinotecan, lapatinib, Daunorubicin, doxorubicin,
mitoxantrone, topotecan) mitoxantrone, topotecan imatinib, irinotecan, lapatinib,
(BCRP substrates) concentrations may increase. mitoxantrone or topotecan:
careful monitoring for any
(BCRP inhibition) occurrence of drug toxicity, and
dose reduction if required.
Antiemetics
Aprepitant Not studied. Co-administration should be
(mild CYP3A4/5 inducer) Isavuconazole concentrations may avoided unless the potential
decrease. benefit is considered to outweigh
the risk.
(CYP3A4/5 induction)
Antidiabetics
Metformin Metformin: No isavuconazole dose
(OCT1, OCT2 and MATE1 AUCinf: ↑ 52% adjustment necessary.
substrate) Cmax: ↑ 23% Metformin: dose reduction may
be required.
(OCT2 inhibition)
Repaglinide Repaglinide: No isavuconazole dose
(CYP2C8 and OATP1B1 AUCinf: ↓ 8% adjustment necessary.
substrate) Cmax: ↓ 14% Repaglinide: no dose adjustment
required.
Pioglitazone Not studied. Co-administration should be
(mild CYP3A4/5 inducer) Isavuconazole concentrations may avoided unless the potential
decrease. benefit is considered to outweigh
the risk.
(CYP3A4/5 induction)
Anticoagulants
Dabigatran etexilate Not studied. No isavuconazole dose
(P-gp substrate) Dabigatran etexilate concentrations adjustment necessary.
may increase. Dabigatran etexilate has a narrow
therapeutic index and should be
(P-gp inhibition). monitored, and dose reduction if
required.
Warfarin S-warfarin No isavuconazole dose
(CYP2C9 substrate) AUCinf: ↑ 11% adjustment necessary.
Cmax: ↓ 12% Warfarin: no dose adjustment
R-warfarin required.
AUCinf: ↑ 20%
Cmax: ↓ 7%
Antiretroviral agents
Lopinavir 400 mg / Ritonavir Lopinavir: No isavuconazole dose
100 mg AUCtau: ↓ 27% adjustment necessary; caution is
(CYP3A4/5 strong inhibitors Cmax: ↓ 23% advised as adverse drug reactions
and substrates) Cmin, ss: ↓ 16%a) may increase.
Ritonavir:
AUCtau: ↓ 31% Lopinavir/ritonavir: no dose
Cmax: ↓ 33% adjustment for lopinavir 400 mg /
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): aprepitant (HOS-112506) daunorubicin (HOS-089674) doxorubicin (HOS-084538) imatinib (HOS-110212) irinotecan (HOS-112102) lapatinib (HOS-122565) mitoxantrone (HOS-124775) topotecan (HOS-086047) metformin (HOS-091032) repaglinide (HOS-086935) pioglitazone (HOS-089663) dabigatran etexilate (HOS-086233) warfarin (HOS-085950) lopinavir (HOS-086269) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage 850ab84615b3abfe437182a0864ac0bf00ab067f02f0d89de60b13f59802225e · Zeichen 12228–16452 im Abschnitt
Wechselwirkungen · Abiraterone Mylan
Abiraterone Mylan 500 mg film-coated tablets Abiraterone Mylan 1000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-146775 · Präparat HOS-099564
In a CYP2C8 drug-drug interaction study in healthy subjects, the AUC of pioglitazone was increased
by 46% and the AUCs for M-III and M-IV, the active metabolites of pioglitazone, each decreased by
10% when pioglitazone was given together with a single dose of 1000 mg abiraterone acetate. Patients
should be monitored for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic
index if used concomitantly. Examples of medicinal products metabolised by CYP2C8 include
pioglitazone and repaglinide (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pioglitazone (HOS-089663) repaglinide (HOS-086935)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T13:57:00Z · SHA-256 a224b8fadc2ad3e1b1af874d8687b8e3d6bb14c5f714b2308f5ba81c1b78da11 · Passage 5bd476b55d4408c2c821b43fcb50044047964016ba4b439b1cd44578d08fbbec · Zeichen 2208–2741 im Abschnitt
Wechselwirkungen · Jaypirca
Jaypirca 50 mg film-coated tablets Jaypirca 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-149909 · Präparat HOS-100173
CYP2C8 substrates
Pirtobrutinib is a moderate inhibitor of CYP2C8. Pirtobrutinib increased the AUC and Cmax of
repaglinide (a substrate of CYP2C8) by 130 % and 98 %, respectively. Therefore, since pirtobrutinib
can increase the plasma concentrations of CYP2C8 substrates, caution is advised when
co-administering with CYP2C8 substrates (e.g. repaglinide, dasabuvir, selexipag, rosiglitazone,
pioglitazone, and montelukast).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pioglitazone (HOS-089663) montelukast (HOS-122836) repaglinide (HOS-086935) dasabuvir (HOS-110302) selexipag (HOS-131246) rosiglitazone (HOS-089664)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-15T09:42:02Z · SHA-256 ac51358255b0e15966ab90f4c5f817ad50f84358de56be652a1c06ce9fa9a7c6 · Passage 5d90d59981f30376d23b297966141888be8f166b96328301c892e8942d5d9c3d · Zeichen 1132–1555 im Abschnitt
Wechselwirkungen · Akeega
Akeega 50 mg/500 mg film-coated tablets Akeega 100 mg/500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-150310 · Präparat HOS-100288
CYP2C8 substrates
Abiraterone is an inhibitor of CYP2C8. In a clinical study in healthy subjects, the AUC of
pioglitazone, a CYP2C8 substrate, was increased by 46% and the AUCs for M-III and M-IV, the
active metabolites of pioglitazone, each decreased by 10% when pioglitazone was given together with
a single dose of 1 000 mg abiraterone acetate. Patients should be monitored for signs of toxicity
related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with Akeega
because of the abiraterone acetate component. Examples of medicinal products metabolised by
CYP2C8 include pioglitazone and repaglinide (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pioglitazone (HOS-089663) repaglinide (HOS-086935)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T15:30:00Z · SHA-256 1bec7f3e5f18e4fe578c0f49b6a9128776963f703a1a9503180dea643f434459 · Passage 1d21ff94e97a4e71afd066379feffd1c0384158e87b397de5a77b2216bb79756 · Zeichen 1953–2602 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.